Humacyte, Inc. (HUMA) stock
HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.50−0.00 (-0.20%)
Close on Nov 18, 2026Market cap $138.90MP/E –Yield –
Humacyte gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Humacyte's gross profit for the twelve months ending Jun 30, 2026 was -$10.49M, down 2390.4% year over year. For fiscal 2025 it was -$7.66M.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.66M | – |
| FY2024 | Dec 31, 2024 | $0 | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$825.00K | -1037.5% |
| Q1 FY2026 | Mar 31, 2026 | -$1.54M | -517.0% |
| Q4 FY2025 | Dec 31, 2025 | -$8.62M | – |
| Q3 FY2025 | Sep 30, 2025 | $493.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $88.00K | – |
| Q1 FY2025 | Mar 31, 2025 | $370.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $0 | – |
| Q2 FY2024 | Jun 30, 2024 | $0 | – |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
See a number that looks wrong?